Brain Targeted Liposomal Drug Delivery System Development Service

Comprehensive Services for Brain Targeted Liposomal Drug Delivery System Development

BOC Sciences delivers an integrated, technically advanced service portfolio specifically tailored to support the development of brain-targeted liposomal drug delivery systems for preclinical research. Our offerings span from specialized lipid materials to fully customized liposomal formulation services designed to cross the blood-brain barrier and achieve high-precision CNS delivery.

Step-by-Step Process of Brain Targeted Liposomal Drug Delivery System Development

1. Project Consultation and Feasibility Analysis

• We start by reviewing your compound, indication, and targeting requirements to define an optimal liposomal strategy.

2. Target Ligand Selection and Conjugation Strategy

• Based on BBB biology, we select and conjugate the appropriate ligand to the liposome surface to ensure active targeting.
• Surface modification with brain-targeting ligands (peptides, antibodies, aptamers)
• Controlled size and charge tuning for optimal BBB penetration
• Dual and multi-drug encapsulation strategies

3. Formulation Design and Optimization

• Through iterative formulation, we balance encapsulation efficiency, particle size, surface charge, and stability.

4. In Vitro Evaluation & In Vivo Preclinical Assessment

• Using BBB-mimicking models, we assess transport efficiency, cytotoxicity, and cellular uptake.
• Biodistribution and brain uptake studies validate targeting efficacy, while PK/PD data support dose strategy design.

5. Stability and Scalability Testing

• Accelerated and long-term stability studies under ICH guidelines
• Liposome batch reproducibility and process scale-up evaluation

Benefits of Our Brain Targeted Liposomal Drug Delivery System Development

BOC Sciences offers unparalleled expertise in self-adjuvanting liposomal vaccine development. Our advantages include:

Applications of Our Brain Targeted Liposomal Drug Delivery System Development

The ability to deliver therapeutic agents precisely to the brain is revolutionizing preclinical research and the development of treatments for central nervous system (CNS) disorders. Brain-targeted liposomal delivery systems offer unique advantages in increasing drug solubility, improving pharmacokinetics, and reducing systemic toxicity—all essential for addressing the complex pathophysiology of neurological diseases.

Neurodegenerative Disorders

Diseases such as Alzheimer's, Parkinson's, and Huntington's are marked by progressive neuronal loss, often localized to specific brain regions. Liposomes functionalized with BBB-penetrating ligands can deliver neuroprotective compounds, anti-amyloid agents, or mitochondrial stabilizers directly to affected tissues. For example, transferrin- or lactoferrin-modified liposomes have been employed to facilitate the delivery of acetylcholinesterase inhibitors or anti-aggregative peptides in preclinical Alzheimer's models, resulting in improved cognitive function and reduced plaque burden.

Brain Tumors and Gliomas

Malignant gliomas are among the most aggressive and drug-resistant brain cancers due to their infiltrative nature and the restrictive BBB. Liposomes engineered with ligands such as angiopep-2 or RGD peptides can selectively home in on tumor vasculature or integrin-overexpressing glioma cells. Encapsulation of chemotherapeutics like doxorubicin or temozolomide in PEGylated liposomes has shown significantly enhanced tumor accumulation and reduced systemic side effects in orthotopic glioblastoma models. Our liposomal systems can be tailored for co-delivery strategies, combining cytotoxic agents and siRNA for synergistic tumor inhibition.

Neuroinflammation and Ischemic Stroke

Liposomes carrying anti-inflammatory agents such as dexamethasone, minocycline, or antioxidants can be directed to sites of neuroinflammation associated with stroke, multiple sclerosis, or traumatic brain injury. Liposomes modified with cell-penetrating peptides or macrophage-homing ligands can cross the BBB and accumulate in inflamed tissues, promoting neuronal survival and functional recovery. In ischemia-reperfusion models, such systems have shown reductions in infarct size and inflammatory cytokine expression.

Psychiatric and Behavioral Disorders

Emerging studies suggest that liposomal delivery of neuromodulatory compounds (e.g., serotonin or dopamine analogs, NMDA receptor modulators) can enhance therapeutic responses in disorders such as depression, schizophrenia, or anxiety. By targeting specific brain regions, these systems can minimize peripheral side effects and improve CNS bioavailability—crucial for drugs with poor BBB permeability or narrow therapeutic windows.

Genetic and Rare Neurological Disorders

Liposomal carriers can serve as efficient vectors for gene editing tools (e.g., CRISPR/Cas9) or RNA therapeutics (e.g., antisense oligonucleotides, siRNA) in treating inherited CNS disorders. Conditions such as spinal muscular atrophy, lysosomal storage diseases, and leukodystrophies may benefit from CNS-targeted delivery of therapeutic nucleic acids. Our systems can be engineered for sustained release, endosomal escape, and region-specific targeting—essential for long-term genetic correction and disease modification.

CNS Infectious Diseases

In conditions like HIV-associated neurocognitive disorders (HAND) or neurotuberculosis, liposomal systems enable the delivery of antiviral or antibacterial agents across the BBB—often a limiting factor in standard treatments. Liposomes help achieve therapeutic concentrations in the brain parenchyma without systemic toxicity, opening new preclinical research directions for CNS-targeted anti-infective strategies.

FAQs – Insights about Our Brain Targeted Liposomal Drug Delivery System Development

How do you ensure that liposomes effectively cross the blood-brain barrier (BBB)?

We employ ligand-mediated targeting strategies such as transferrin, RVG peptide, angiopep-2, and antibody conjugation to facilitate receptor-mediated transcytosis across the BBB. Additionally, our in vitro BBB models simulate tight junction integrity, and all candidate formulations are screened in preclinical in vivo models for brain uptake efficiency.

What is the typical size range of your brain-targeted liposomes, and why does it matter?

Our liposomes are typically engineered within the 80–150 nm range, which balances prolonged systemic circulation and efficient BBB penetration. Size is tightly controlled using dynamic light scattering (DLS) and extrusion methods to ensure optimal biodistribution and targeting efficiency.

What is the advantage of using liposomal carriers for CNS drug delivery compared to other nanoparticle systems?

Liposomal systems are biocompatible, biodegradable, and less immunogenic than many synthetic nanocarriers. Their lipid-based composition mimics biological membranes, allowing for superior BBB interaction and minimal systemic toxicity. Surface functionalization further enhances their targeting specificity and pharmacokinetics.

Can you develop dual-targeted liposomes (e.g., BBB + tumor-specific)?

Yes. We have experience in dual-ligand surface engineering for complex targeting scenarios, such as liposomes designed to first cross the BBB and then target glioblastoma or metastatic lesions via tumor-specific ligands (e.g., folate, EGFR antibodies).

Can you support projects requiring targeted delivery of nucleic acids or gene editing tools to the brain?

Absolutely. We provide liposomal encapsulation and delivery systems for siRNA, miRNA, mRNA, and CRISPR-Cas components, with a focus on achieving brain-specific uptake and expression. We validate cellular uptake, endosomal escape, and gene silencing efficacy in relevant neuronal models.

To accelerate your brain-targeted therapeutic programs, contact BOC Sciences today and explore how our liposomal innovation can deliver your molecule—where it matters most.